We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Clariane SE | EU:CLARI | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.324 | -13.81% | 2.022 | 1.98 | 2.05 | 2.364 | 1.93 | 2.36 | 1,843,319 | 16:40:00 |
From May 2024 to Jun 2024
Key transaction terms:
Regulatory News:
NOT TO BE PUBLISHED, DISTRIBUTED OR CIRCULATED DIRECTLY OR INDIRECTLY IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES IN THE UNITED STATES OF AMERICA OR ANY OTHER COUNTRY.
THIS PRESS RELEASE IS AN ADVERTISEMENT AND NOT A PROSPECTUS WITHIN THE MEANING OF REGULATION (EU) 2017/1129 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF JUNE 14, 2017.
Clariane (CLARIA.PA – ISIN FR0010386334) (the “Company”), takes a decisive step forward in the completion of its financial structure strengthening with the announcement today of the launch of a capital increase in cash with shareholders’ preferential subscription rights for an amount of approximately €237 million (the “Rights Issue”), subsequent to a €92.1 million reserved capital increase approved at the general meeting of shareholders held on 10 June 2024 and completed on 12 June 2024 (the “Reserved Capital Increase” and together with the Rights Issue, the “Capital Increases”).
Reminder on the Plan to strengthen the financial structure of Clariane announced on 14 November 2023
The Rights Issue is carried out in the context of Clariane’s €1.5 billion plan to strengthen its financial structure and reduce its debt, announced by the Company on 14 November 2023.
This plan is designed to secure and accelerate Clariane's debt reduction path and enable the Group to benefit from a financial structure adapted to a more challenging economic environment triggered by inflation, interest rates rise and more complex access to debt and real-estate markets, and finally to provide some flexibility in the execution of its strategy.
The Capital Increases are coming as the third step of such plan.
The Company completed the first two steps of its plan in December 2023:
At the same time, the Group has also embarked on the fourth and last step of its plan with a program of disposals of operating and real-estate of assets, as well as capital partnerships, aimed in particular at a geographical refocusing of its activities with of approximately €1 billion expected gross proceeds. With the disposals of the United Kingdom and Netherlands completed during the first quarter of 2024, and the planned sale of its “Hospitalisation à Domicile” (HAD) business in France announced on 6 May 2024, which received a favourable opinion from employee representative bodies on 14 May 2024, the Group has committed, to date, around 40% the planned disposal program.
The Rights Issue is subsequent to the Reserved Capital Increase of €92.1 million approved on 10 June 2024 at the Combined General Meeting of Shareholders and which settlement/delivery occurred on 12 June 2024. The Reserved Capital Increase was subscribed by investment group HLD Europe for c. €74.1 million, investment funds Flat Footed for c. €15 million and Leima Valeurs for c. €3 million.
The net proceeds of approximately €90 million from the Reserved Capital Increase will be allocated to the early repayment of the real estate bridge loan set up on 27 December 2023, which matures on 31 January 2025, so that the balance of the bridge loan will consequently be reduced to 85 million euros.
Following completion of the Reserved Capital Increase and prior to the launch of the Rights Issue, HLD Europe holds 20.02% (and 25.67% after the agreement entered into on 11 June 2024 to acquire all shares held by Holding Malakoff Humanis after Rights have detached) of the Company’s share capital, Flat Footed holds 10.53% of the Company’s share capital and Leima Valeurs holds 5.18% of the Company’s share capital.
Main terms of the Rights Issue
The Rights Issue will be carried out with shareholders’ preferential subscription rights (the “Rights”), pursuant to the 2nd resolution of the general meeting of shareholders held on 26 March 2024, and will result in the issue of 213,588,456 new ordinary shares (the “New Shares”), at a subscription price of €1.11 per New Share (i.e. €0.01 nominal value and €1.10 issue premium), representing gross proceeds, including the issue premium, of €237,083,186.16.
Each shareholder will receive one (1) Right per each share held in a securities account as at the end of 17 June 2024. In order to allow the registration in the securities account as of such date, purchases in the market of existing shares must occur on 13 June 2024 at the latest. 2 Rights held will entitle their holder to subscribe on an irreducible basis (à titre irréductible) for 3 New Shares. Thus, a shareholder holding 2 existing shares will be able to subscribe to 3 New Shares at a total subscription price of €3.33. Rights will be detached from existing shares on 14 June 2024 and existing shares will thus be tradeable ex-rights from 14 June 2024.
Subscriptions on a reducible basis (à titre réductible) will be accepted. Any New Shares not absorbed on an irreducible basis will be allocated to the holders of the Rights having submitted additional subscription orders on a reducible basis subject to reduction in the event of oversubscription.
Based on the closing price of the Clariane shares on the regulated market of Euronext in Paris (“Euronext Paris”) on 11 June 2024, i.e. €3.20, and on the subscription price of €1.11 per New Share (i.e. €0.01 of nominal value and €1.10 of issue premium), the theoretical value of one (1) Right is €1.254, the theoretical ex-right price of the share is €1.946.
For indicative purposes, the subscription price reflects a discount of 43.0% to the theoretical ex-right share price (calculated on the closing price on 11 June 2024) and 65.3% to the Clariane’s share closing price on 11 June 2024.
These values do not necessarily reflect the value of the Rights during their trading period, the ex-right price of a Clariane existing share or the discounts, as observed in the market.
The Rights Issue will be open to the public in France only.
These capital increases mainly aim at reducing the Company’s debt and strengthening its financial structure, as well as supporting its "At your side” corporate project and its commitments as a purpose-driven company.
The net proceeds of the Rights Issue, estimated at approximately €234 million, will be allocated as follows: up to an amount of €85 million to the early repayment of the remaining balance of the real estate bridge loan and up to an amount of €149 million to strengthen the Company’s liquidity in order to enable it to meet its debt maturities over a period of 12 months from the end of May 2024, including €88 million of Schuldschein maturing in December 2024 and real estate debt amortization scheduled each month for a total of €115 million. The amount of debt not covered by the proceeds of the Capital Increases (approximately €54 million) may be covered by the Company's liquidities, amounting to €447 million as of 31 March 2024.
Following the Rights Issue's completion, the Company will have sufficient working capital to meet its obligations over the next 12 months from 12 June 2024. After repayment of the above-mentioned debt maturities using the proceeds of the Capital Increases and the Group's cash, the Company will be able to satisfy to the minimum liquidity condition of €300 million in order to renew its RCF facility if necessary.
BNP Paribas, Crédit Agricole Corporate and Investment Bank, Natixis and Société Générale are acting as joint global coordinators and joint bookrunners (the “Joint Global Coordinators and Joint Bookrunners”) in respect of the Rights Issue.
Crédit Agricole Corporate and Investment Bank and Rothschild & Co act as financial advisor to the Company, Darrois Villey Maillot Brochier and Davis Polk & Wardwell LLP as legal advisors to the Company and A&O Shearman as legal advisor to the Joint Global Coordinators and the Joint Global Bookrunners.
Indicative Timetable for the Rights Issue
The Rights will be detached on 14 June 2024 and tradeable from 14 June 2024 until 26 June 2024 inclusive on Euronext Paris under ISIN code FR001400QSF6. Unexercised Rights will automatically lapse at the end of the subscription period, i.e. on 28 June 2024. The New Shares subscription period will be open from 18 June 2024 until 28 June 2024 (inclusive).
The issuance, settlement and delivery of the New Shares and their admission to trading on Euronext Paris are expected to take place on 5 July 2024. The New Shares will immediately entitle their holders, from the date of issuance, to receive all dividends and distribution decided by the Company from this date. They will be immediately assimilated with existing shares of the Company and will be traded on the same trading line under the same ISIN code (FR0010386334).
Subscription commitments
As indicated in its press release dated 17 May 2024, Crédit Agricole Assurances through its subsidiary Predica, aiming to maintain its current shareholding in Clariane following the Capital Increases at least equal to that which it held prior to the completion of the Reserved Capital Increase (i.e., 24.64% of the capital), has entered into on 16 May 2024 an agreement with Holding Malakoff Humanis to acquire in the context of the Rights Issue, part or all of the subscription rights of Holding Malakoff Humanis at their theoretical value with the intention to exercise all or part of the rights acquired. Furthermore, with this same holding objective, on 4 June 2024 Predica entered into an agreement to acquire the entire stake of Investissements PSP in the Company, resulting in it holding approximately 21.1% of the Company’s share capital following the settlement of the transaction on 13 June 2024 as a result of the completion of the Reserved Capital Increase.
HLD indicated that it entered into an agreement on 11 June 2024 to acquire all of the shares held by Holding Malakoff Humanis (i.e. 5.7% of the capital based on the current Company’s share capital), excluding of the Rights linked to the Rights Issue, subject to the condition precedent of the detachment of the said rights, and having to take place prior to the settlement and delivery of the Rights Issue.
At the date of the prospectus relating to the Rights Issue (the “Prospectus”), the Company has received subscription commitments from Crédit Agricole Assurances through its subsidiary Predica, HLD Europe, Flat Footed and Leima Valeurs covering the full amount of the Rights Issue. These commitments are as follows:
Mrs. Sophie Boissard, CEO, holding 83,934 existing shares, also indicated that she would participate in the Rights Issue on an irreducible basis prorata to her stake in the Company’s share capital.
As of the date of the Prospectus, the Company is not aware of the intention of other shareholders holding more than 5% of the capital or members of its administrative or management bodies to participate in the Rights Issue.
The Rights Issue is not subject to an underwriting agreement by any banking syndicate.
Fairness Opinion from an Independent expert
The Company appointed on a voluntary basis the firm Finexsi, located at 14 rue Bassano, 75116 Paris, France as independent assessor, in accordance with Article 261-3 of the Autorité des marchés financiers (“AMF”) General Regulation, in order to establish a supplement to the fairness certificate relating to the Rights Issue. The addendum dated 12 June 2024, completing the initial Fairness Opinion dated 24 May 2024 established as part of the Reserved Capital Increase by the Finexsi Firm is incorporated by reference into the Prospectus (as defined below) related to the Rights Issue, with the consent of Finexsi which has approved its content and allowed the Company to report the conclusion of this opinion.
Lock-up commitments
The Company has agreed to a lock-up period starting on the date of the approval by the AMF of the Prospectus relating to the Rights Issue and expiring 180 calendar days following the settlement-delivery date of the New Shares, subject to certain customary exceptions.
Crédit Agricole Assurances through its subsidiary Predica, HLD Europe, Flat Footed and Leima Valeurs have each undertaken not to increase their respective stake in the Company’s share capital (held directly or indirectly, alone or in concert) beyond 29.99% of the Company’s share capital (and voting rights for Crédit Agricole Assurances through its subsidiary Predica)(subject to certain customary exceptions), for a period of 12 months in the case of Crédit Agricole Assurances / Predica and 36 months in the case of HLD Europe, Flat Footed and Leima Valeurs.
HLD Europe, Flat Footed and Leima Valeurs have also undertaken to hold the shares subscribed under the Reserved Capital Increase for a period of 18 months following the completion of the Rights Issue.
Each of Crédit Agricole Assurances via its subsidiary Predica, HLD, Flat Footed, and Leima Valeur has agreed to a lock-up on the New Shares, starting on the date of approval by the Autorité des marchés financiers (“AMF”) of the prospectus relating to the rights issue and ending 90 calendar days after the settlement and delivery of the New Shares, subject to certain customary exceptions.
Finally, Credit Agricole Assurances through its subsidiary Predica, HLD Europe, Flat Footed and Leima Valeurs have committed not to act in concert.
Dilution
For illustrative purposes only, a shareholder holding 1% of the share capital of the Company on 12 June 2024 on a non-dilutive basis and not subscribing to the Rights Issue would hold, on a non-diluted basis and after issuance of the New Shares, 0.40% of the Company’s share capital, and on a diluted2 basis and after issuance of the New Shares, 0.38% of the Company’s share capital.
For illustrative purposes only, based on the number of shares in circulation at the date of the Prospectus, the split of the Company's shareholding at the date of the Prospectus and the subscription commitments, and taking into account the subscription to the Rights Issue at 100% and assuming the exercise of all Rights (no subscription on a reducible basis), the share capital and voting rights of the Company would be split as follows:
Shareholders
Number of shares
% of share capital
Number of voting rights
% of voting rights (a)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Predica (b)
86,434,601
86,434,601
24.28%
23.16%
86,434,601
86,434,601
24.28%
23.16%
HLD (c)
79,298,260
79,298,260
22.28%
21.25%
79,298,260
79,298,260
22.28%
21.25%
Flat Footed (d)
37,489,110
37,959,344
10.53%
10.17%
37,489,110
37,959,344
10.53%
10.17%
Leima Valeurs
18,423,541
18,423,541
5.18%
4.94%
18,423,541
18,423,541
5.18%
4.94%
Treasury shares (e)
279,094
279,094
0.08%
0.07%
279,094
279,094
0.08%
0.07%
Float (f)
134,056,155
150,781,207
37.66%
40.40%
134,056,155
150,781,207
37.66%
40.40%
Total
355,980,761
373,176,047
100.00%
100.00%
355,980,761
373,176,047
100.00%
100.00%
(a) % of voting rights = gross voting rights, including those attached to treasury shares. Treasury shares are deprived of voting rights exercisable at a general meeting. Number of voting rights exercisable as of 12 June 2024: 372,896,953
(b) Taking into account the acquisition by Predica of the entire stake of Investissements PSP in the Company as per a firm agreement concluded on 4 June 2024, the settlement and delivery of which should take place on 13 June 2024, as announced by Predica in a press release dated 5 June 2024.
(c) Taking into account the acquisition by HLD of the entire stake of Holding Malakoff Humanis in the Company (ex Rights), subject to the condition precedent of the detachment of the rights linked to the Rights Issue.
(d) Flat Footed holds (i) 344,258 ODIRNANE, which exercise can take place at any time until 8 September 2026 and which can give right to 364,569 CLARIANE SE shares according to a conversion rate of 1.059 and (ii) 90,467 OCEANE, which exercise can take place at any time until 6 March 2027 and can give right to 105,665 CLARIANE SE shares based on a conversion rate of 1.168. It is specified that no opposition was filed within the time limit set by the Ministry of the Economy as part of the notification for the purposes of exemption from authorization provided for in article R. 151-5 third paragraph of the monetary and financial code in respect of foreign investments, thus allowing Flat Footed to cross the threshold of 10% of the Company’s voting rights.
(e) Treasury shares held as part of the liquidity contract (258,544 shares as of 11 June 2024) and the share buyback program (20,550 shares as of 11 June 2024).
(f) The free float is defined by difference with other shareholders holding 5% or more of the capital and voting rights.
(1) In the event of definitive acquisition of all 2,398,781 shares allocated free of charge, of the issue of 7,950,981 shares upon exercise of the right to the allocation/exchange of shares in respect of the 7,508,009 ODIRNANE in circulation and of the issue of 6,845,524 shares in the event of conversion of the 5,860,894 OCEANEs in circulation.
For illustrative purposes only, based on the number of shares in circulation at the date of the Prospectus, the split of the Company's shareholding at the date of the Prospectus and the subscription commitments, and assuming a subscription on an irreducible basis only to the Rights Issue up to 50% by the Rights holders other than Predica, HLD, Flat Footed and Leima Valeurs, and after allocation of orders on a reducible basis from Predica, HLD, Flat Footed and Leima Valeurs, the share capital and voting rights would be split as follows:
Shareholders
Number of shares
% of share capital
Number of voting rights
% of voting rights (a)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Predica (b)
103,623,894
103,623,894
29.11%
27.77%
103,623,894
103,623,894
29.11%
27.77%
HLD (c)
92,320,632
92,320,632
25.93%
24.74%
92,320,632
92,320,632
25.93%
24.74%
Flat Footed (d)
44,340,999
44,811,233
12.46%
12.01%
44,340,999
44,811,233
12.46%
12.01%
Leima Valeurs
21,790,814
21,790,814
6.12%
5.84%
21,790,814
21,790,814
6.12%
5.84%
Treasury shares (e)
279,094
279,094
0.08%
0.07%
279,094
279,094
0.08%
0.07%
Float (f)
93,625,328
110,350,380
26.30%
29.57%
93,625,328
110,350,380
26.30%
29.57%
Total
355,980,761
373,176,047
100.00%
100.00%
355,980,761
373,176,047
100.00%
100.00%
(a) % of voting rights = gross voting rights, including those attached to treasury shares. Treasury shares are deprived of voting rights exercisable at a general meeting. Number of voting rights exercisable as of 12 June 2024: 372,896,953
(b) Taking into account the acquisition by Predica of the entire stake of Investissements PSP in the Company as per a firm agreement concluded on 4 June 2024, the settlement and delivery of which should take place on 13 June 2024, as announced by Predica in a press release dated 5 June 2024.
(c) Taking into account the acquisition by HLD of the entire stake of Holding Malakoff Humanis in the Company (ex Rights), subject to the condition precedent of the detachment of the rights linked to the Rights Issue.
(d) Flat Footed holds (i) 344,258 ODIRNANE, which exercise can take place at any time until 8 September 2026 and which can give right to 364,569 CLARIANE SE shares according to a conversion rate of 1.059 and (ii) 90,467 OCEANE, which exercise can take place at any time until 6 March 2027 and can give right to 105,665 CLARIANE SE shares based on a conversion rate of 1.168. It is specified that no opposition was filed within the time limit set by the Ministry of the Economy as part of the notification for the purposes of exemption from authorization provided for in article R. 151-5 third paragraph of the monetary and financial code in respect of foreign investments, thus allowing Flat Footed to cross the threshold of 10% of the Company’s voting rights.
(e) Treasury shares held as part of the liquidity contract (258,544 shares as of 11 June 2024) and the share buyback program (20,550 shares as of 11 June 2024).
(f) The free float is defined by difference with other shareholders holding 5% or more of the capital and voting rights.
(1) In the event of definitive acquisition of all 2,398,781 shares allocated free of charge, of the issue of 7,950,981 shares upon exercise of the right to the allocation/exchange of shares in respect of the 7,508,009 ODIRNANE in circulation and of the issue of 6,845,524 shares in the event of conversion of the 5,860,894 OCEANEs in circulation.
For illustrative purposes only, based on the number of shares in circulation at the date of the Prospectus, the split of the Company's shareholding at the date of the Prospectus and the subscription commitments, and assuming a subscription on an irreducible basis only to the Rights Issue up to 0% by the Rights holders other than Predica, HLD, Flat Footed and Leima Valeurs, and after allocation of orders on a reducible basis from Predica, HLD, Flat Footed and Leima Valeurs, the share capital and voting rights would be split as follows:
Shareholders
Number of shares
% of share capital
Number of voting rights
% of voting rights (a)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Non diluted basis
Diluted basis (1)
Predica (b)
106,354,798
106,354,798
29.88%
28.50%
106,354,798
106,354,798
29.88%
28.50%
HLD (c)
106,354,798
106,354,798
29.88%
28.50%
106,354,798
106,354,798
29.88%
28.50%
Flat Footed (d)
60,208,754
60,678,988
16.91%
16.26%
60,208,754
60,678,988
16.91%
16.26%
Leima Valeurs
29,588,817
29,588,817
8.31%
7.93%
29,588,817
29,588,817
8.31%
7.93%
Treasury shares (e)
279,094
279,094
0.08%
0.07%
279,094
279,094
0.08%
0.07%
Float (f)
53,194,500
69,919,552
14.94%
18.74%
53,194,500
69,919,552
14.94%
18.74%
Total
355,980,761
373,176,047
100.00%
100.00%
355,980,761
373,176,047
100.00%
100.00%
(a) % of voting rights = gross voting rights, including those attached to treasury shares. Treasury shares are deprived of voting rights exercisable at a general meeting. Number of voting rights exercisable as of 12 June 2024: 372,896,953
(b) Taking into account the acquisition by Predica of the entire stake of Investissements PSP in the Company as per a firm agreement concluded on 4 June 2024, the settlement and delivery of which should take place on 13 June 2024, as announced by Predica in a press release dated 5 June 2024.
(c) Taking into account the acquisition by HLD of the entire stake of Holding Malakoff Humanis in the Company (ex Rights), subject to the condition precedent of the detachment of the rights linked to the Rights Issue.
(d) Flat Footed holds (i) 344,258 ODIRNANE, which exercise can take place at any time until 8 September 2026 and which can give right to 364,569 CLARIANE SE shares according to a conversion rate of 1.059 and (ii) 90,467 OCEANE, which exercise can take place at any time until 6 March 2027 and can give right to 105,665 CLARIANE SE shares based on a conversion rate of 1.168. It is specified that no opposition was filed within the time limit set by the Ministry of the Economy as part of the notification for the purposes of exemption from authorization provided for in article R. 151-5 third paragraph of the monetary and financial code in respect of foreign investments, thus allowing Flat Footed to cross the threshold of 10% of the Company’s voting rights.
(e) Treasury shares held as part of the liquidity contract (258,544 shares as of 11 June 2024) and the share buyback program (20,550 shares as of 11 June 2024).
(f) The free float is defined by difference with other shareholders holding 5% or more of the capital and voting rights.
(1) In the event of definitive acquisition of all 2,398,781 shares allocated free of charge, of the issue of 7,950,981 shares upon exercise of the right to the allocation/exchange of shares in respect of the 7,508,009 ODIRNANE in circulation and of the issue of 6,845,524 shares in the event of conversion of the 5,860,894 OCEANEs in circulation.
In addition, and in accordance with the undertakings it gave when it became a purpose driven company (Société à Mission) in 2023 and the resolutions adopted by the Combined General Meeting of 26 March 2024, the Company plans to launch, depending on market conditions, in the coming months, a capital increase reserved for its employees, which will enable them to be fully involved in the Group's plan to strengthen its financial structure and its "At your side” corporate project.
Availability of the prospectus
The Prospectus in the French language approved by the AMF under number 24-214 on 12 June 2024 and comprised of (i) Clariane 2023 universal registration document filed with the AMF on 30 April 2024 under number D. 24-0380 (the “Universal Registration Document”), (ii) a first amendment to the URD filed with the AMF on 31 May 2024 under number D.24-0380-A01 (the “First Amendment”), (iii) a second amendment to the Universal Registration Document filed with the AMF on 12 June 2024 under number D.24-0380-A02 (the "Second Amendment” and with the First Amendment, the “Amendments”), (iv) the securities note dated 12 June 2024 (the “Securities Note”) and (v) the summary of the Prospectus (included in the Securities Note) is available on the websites of the AMF (www.amf-france.org) and the Company (www.clariane.com). Copies of the Prospectus are available free of charge at the Company’s registered office (21-25 rue Balzac, 75008 Paris, France). Copies of the Prospectus are not and will not be made available in the United States of America.
Potential investors are advised to read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the New Shares. The approval of the Prospectus by the AMF should not be understood as a favorable opinion on the issuer and on the quality of the financial securities covered by the Prospectus.
Risk factors
Investors’ attention is drawn to the risk factors relating to the Company included in chapter 2 « Risk Factors » of the Universal Registration Document as updated by the Amendments, in Chapter 2 of the Second Amendment, and the risk factors relating to the transaction and the New Shares mentioned in Chapter 2 “Risk Factors” of the Securities Note.
Disclaimer
This press release includes "forward-looking statements". All statements other than statements of historical facts included in this press release, including, without limitation, those regarding Clariane’s financial position, business strategy, plans and objectives of management for future operations, are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are beyond Clariane S.E.’s control, which may cause the actual results, performance or achievements of Clariane, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Clariane’s present and future business strategies and the environment in which Clariane will operate in the future. Additional factors could cause actual results, performance or achievements to differ materially.
All forward-looking statements included in this press release speak only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond what is required by applicable regulations. Neither Clariane S.E., nor any of its directors, officers, employees, agents, affiliates or advisers accepts any responsibility whatsoever for the reasonableness of assumptions made or opinions stated or the likelihood of the achievement of projections, prospects or returns. Any responsibility or liability for any such information is expressly disclaimed. Nothing in this press release is, or should be relied upon as, a promise or representation of the future. In addition, no statement in this press release is intended to be nor may be construed as a profit forecast. Past performance of Clariane S.E. cannot be relied on as a guide to future performance.
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of ordinary shares in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.
This press release is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (as amended the “Prospectus Regulation”). Potential investors are advised to read the prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the securities. The approval of the prospectus by the AMF should not be understood as an endorsement of the securities offered or admitted to trading on a regulated market.
With respect to the Member States of the European Economic Area (other than France) and the United Kingdom (each a “Relevant State”), no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any Relevant State. As a result, the securities may and will be offered in any Relevant State only (i) to qualified investors within the meaning of the Prospectus Regulation, for any investor in a Member State of the European Economic Area, or Regulation (EU) 2017/1129 as part of national law under the European Union (Withdrawal) Act 2018 (the “UK Prospectus Regulation”), for any investor in the United Kingdom, (ii) to fewer than 150 individuals or legal entities (other than qualified investors as defined in the Prospectus Regulation or the UK Prospectus Regulation, as the case may be), or (iii) in accordance with the exemptions set forth in Article 1 (4) of the Prospectus Regulation or under any other circumstances which do not require the publication by Clariane of a prospectus pursuant to Article 3 of the Prospectus Regulation and/or to applicable regulations of that Relevant State.
The distribution of this press release has not been made, and has not been approved, by an “authorised person” within the meaning of Article 21(1) of the Financial Services and Markets Act 2000. As a consequence, this press release is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.
This press release may not be published, distributed or transmitted in the United States of America (including its territories and dependencies). This press release does not constitute or form part of any offer of securities for sale or any solicitation to purchase or to subscribe for securities or any solicitation of sale of securities in the United States of America. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the law of any State or other jurisdiction of the United States of America, and may not be offered or sold in the United States of America absent registration under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Clariane does not intend to register all or any portion of the securities in the United States of America under the Securities Act or to conduct a public offering of the securities in the United States of America.
This announcement is not, and under no circumstances is it to be construed as, a prospectus, offering memorandum, advertisement or an offer to sell or solicitation of an offer to buy any of the securities referred to herein in Canada.
This announcement may not be published, forwarded or distributed, directly or indirectly, in the United States of America, Canada, Australia or Japan.
About Clariane
Clariane is the leading European community for care in times of vulnerability. It has operations in six countries: Belgium, France, Germany, Italy, the Netherlands, and Spain.
Relying on their diverse expertise, each year the Group’s 60,000 professionals provide services to over 800,000 patients and residents in three main areas of activity: long-term care nursing home (Korian, Seniors Residencias, Berkley, etc.), specialized care facilities and services (Inicea, Ita, Grupo 5, Lebenswert, etc.), and alternative living solutions (Petits-fils, Ages et Vie, etc.).
In June 2023, Clariane became a purpose-driven company and added to its bylaws a new corporate purpose, common to all its activities: “To take care of each person’s humanity in times of vulnerability”.
Clariane has been listed on Euronext Paris since November 2006, In compartment B.
Euronext ticker: CLARI.PA - ISIN: FR0010386334
____________________________ 1 It is specified that no opposition was filed within the time limit set by the Ministry of the Economy as part of the notification for the purposes of exemption from authorization provided for in article R. 151-5 third paragraph of the monetary and financial code in respect of foreign investments, thus allowing Flat Footed to cross the threshold of 10% of the Company’s voting rights. 2 Note: taking into account free shares and shares underlying the, ODIRNANEs and OCEANEs
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612823023/en/
Investors Stéphane Bisseuil Investor Relations Director +33 (0) 6 58 60 68 69 stephane.bisseuil@clariane.com
Press Matthieu Desplats Press Relations Director 06 58 09 01 61 matthieu.desplats@clariane.com
Florian Bachelet Head of press relations 06 79 86 78 23 florian.bachelet@clariane.com
Julie Mary Head of press relations 06 59 72 50 69 julie.mary@clariane.com
1 Year Clariane Chart |
1 Month Clariane Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
